Quick Answer
Vistagen Therapeutics, Inc. reported Net Income of -$51.42 million for fiscal year 2025.
Vistagen Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$51.42M | -75.1% |
| 2024 | -$29.36M | +50.4% |
| 2023 | -$59.25M | -24.0% |
| 2022 | -$47.76M | -166.3% |
| 2021 | -$17.93M | +13.7% |
| 2020 | -$20.77M | +15.5% |
| 2019 | -$24.59M | -71.4% |
| 2018 | -$14.35M | -39.9% |
| 2017 | -$10.26M | +78.3% |
| 2016 | -$47.22M | -240.1% |
| 2015 | -$13.89M | -367.9% |
| 2014 | -$2.97M | +77.0% |
| 2013 | -$12.89M | -5.5% |
| 2012 | -$12.21M | -28.8% |
| 2011 | -$9.48M | -129.9% |
| 2010 | -$4.12M | +12.2% |
| 2009 | -$4.70M | +13.8% |
| 2008 | -$5.45M | -172.4% |
| 2007 | -$2.00M | -12.8% |
| 2006 | -$1.77M | -63.7% |
| 2005 | -$1.08M | +87.6% |
| 2004 | -$8.76M | -1642.0% |
| 2003 | -$502.6K | +76.2% |
| 2002 | -$2.11M | -16.8% |
| 2001 | -$1.81M | -158.4% |
| 2000 | -$700.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$18.90M | -34.1% | +2.7% |
| September 30, 2025 | -$19.42M | -49.8% | -28.6% |
| June 30, 2025 | -$15.10M | -40.6% | -7.1% |
| December 31, 2024 | -$14.09M | -121.9% | -8.7% |
| September 30, 2024 | -$12.96M | -96.7% | -20.8% |
| June 30, 2024 | -$10.73M | -55.5% | -69.0% |
| December 31, 2023 | -$6.35M | +34.9% | +3.6% |
| September 30, 2023 | -$6.59M | +62.3% | +4.6% |
- Vistagen Therapeutics, Inc. showed a decrease of -75.1% in Net Income compared to the prior fiscal year.
- Over the 2000–2025 period, Vistagen Therapeutics, Inc.’s net income has declined by 7245.4% (from -$700.0 thousand to -$51.42 million).
- The most recent figure is from Vistagen Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: